<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eric Deconinck</style></author><author><style face="normal" font="default" size="100%">Celine Vanhee</style></author><author><style face="normal" font="default" size="100%">Peter Keizers</style></author><author><style face="normal" font="default" size="100%">Pauline Guinot</style></author><author><style face="normal" font="default" size="100%">Albena Mihailova</style></author><author><style face="normal" font="default" size="100%">Per Vidar Syversen</style></author><author><style face="normal" font="default" size="100%">Graziella Li-Ship</style></author><author><style face="normal" font="default" size="100%">Steven Young</style></author><author><style face="normal" font="default" size="100%">Agata Blazewicz</style></author><author><style face="normal" font="default" size="100%">Magdalena Poplawska</style></author><author><style face="normal" font="default" size="100%">Josephine Loasby Al-Sayed</style></author><author><style face="normal" font="default" size="100%">Lone Stengelshøj Olsen</style></author><author><style face="normal" font="default" size="100%">Oliver El-Atma</style></author><author><style face="normal" font="default" size="100%">Roman Leist</style></author><author><style face="normal" font="default" size="100%">Karl-Henrik Jönsson</style></author><author><style face="normal" font="default" size="100%">Maria Afxentiou</style></author><author><style face="normal" font="default" size="100%">M Barrios Mendoza</style></author><author><style face="normal" font="default" size="100%">Diaz, I Dorronsoro</style></author><author><style face="normal" font="default" size="100%">Marina Zemser</style></author><author><style face="normal" font="default" size="100%">Alla Kozokin</style></author><author><style face="normal" font="default" size="100%">Andreas Hackl</style></author><author><style face="normal" font="default" size="100%">Maria-Jao Portela</style></author><author><style face="normal" font="default" size="100%">Nico Beerbaum</style></author><author><style face="normal" font="default" size="100%">Marie Bertrand</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study.</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Test Anal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">GEON/OMCL network</style></keyword><keyword><style  face="normal" font="default" size="100%">illegal medicinal products</style></keyword><keyword><style  face="normal" font="default" size="100%">non-ATC-INN drugs</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Apr</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The General European Official Medicines Control Laboratory (OMCL) Network (GEON), co-ordinated by the European Directorate for the Quality of Medicines &amp;amp; HealthCare (EDQM), regularly organises market surveillance studies on specific categories of suspected illegal or illegally traded products. These studies are generally based on a combination of retrospective and prospective data collection over a defined period of time. This paper reports the results of the most recent study in this context with the focus on health products containing non-Anatomical Therapeutic Chemical-International Nonproprietary Name (ATC-INN) molecules. In total 1104 cases were reported by 16 countries for the period between January 2017 and the end of September 2019. The vast majority of these samples (83%) were collected from the illegal market, while only 3% originated from a legal source. For the rest of the samples, categorisation was not possible. Moreover, 69% of all the reported samples were presented as medicines, including sexual performance enhancers, sports performance enhancers, physical performance enhancers and cognitive enhancers or nootropic molecules that act on the central nervous system (CNS). Although the popularity of anabolics, PDE-5 inhibitors and CNS drugs in illegal products has already been reported, the study showed some new trends and challenges. Indeed, 11% of the samples contained molecules of biological origin, that is, research peptides, representing the second most reported category in this study. Furthermore, the study also clearly shows the increasing popularity of Selective Androgen Receptor Modulators and nootropics, two categories that need attention and should be further monitored.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><section><style face="normal" font="default" size="100%">833</style></section></record></records></xml>